Evaluation of Lifetime participation in Intensive Top-level sports and Exercise

Evaluation of Lifetime participation in Intensive Top-level sports and Exercise - ELITE cohort

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55187

Enrollment

3000

Registered

2019-10-04

Start date

2020-05-25

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy

Interventions

nvt

Eligibility

Age

16 Years to 64 Years

Inclusion criteria

Inclusion criteria: >16 years old Registered as elite athletes according to NOC*NSF (A-status, HP-status or selection status) Participation in the SMART screening

Exclusion criteria

Exclusion criteria: Unable to give inform consent

Design outcomes

Primary

Measure	Time frame
The main objective of ELITE is to establish comprehensive cardiac baseline assessment in elite athletes consisting of electrocardiographic characteristics, VO2 max, peak load (in METS or Watt), arrhythmias, cardiac biomarkers, lipid profile, ejection fraction (EF), myocardial wall thickness of the left and right ventricle, volume of left- and right atria and ventricles, myocardial tissue characteristics including fibrosis and oedema using late gadolinium enhancement (LGE), mechanical quantification of body composition, and cardiogenetics. The main endpoint of (sub)study COMMIT are COVID-19 serology and cardiac sequelae, SARS-CoV-2 antibodies, and SARS-CoV-2 specific B-and T-cell responses.	—

Measure

Time frame

The main objective of ELITE is to establish comprehensive cardiac baseline assessment in elite athletes consisting of electrocardiographic characteristics, VO2 max, peak load (in METS or Watt), arrhythmias, cardiac biomarkers, lipid profile, ejection fraction (EF), myocardial wall thickness of the left and right ventricle, volume of left- and right atria and ventricles, myocardial tissue characteristics including fibrosis and oedema using late gadolinium enhancement (LGE), mechanical quantification of body composition, and cardiogenetics. The main endpoint of (sub)study COMMIT are COVID-19 serology and cardiac sequelae, SARS-CoV-2 antibodies, and SARS-CoV-2 specific B-and T-cell responses.

—

Secondary

Measure	Time frame
To investigate the association between cardiogenetics and (sports-related) cardiac indices.	—

Countries

Netherlands

Contacts

Public ContactF.J. Leusden

Amsterdam UMC

sportcardiologie@amsterdamumc.nl0653637755

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)